Evaluating the Primary Prevention of Ischemic Stroke of Oral Antithrombotic Therapy in Head and Neck Cancer Patients with Radiation Therapy

Table 1

Baseline characteristics of head and neck cancer patients with radiation therapy and study population after propensity score matching.

Variables	Study population					Study population after PSM
	Nonuser ()		User ()		value	Nonuser (		User ()		value
		%		%			%		%
Age (years)
<45	11561	31.40	172	21.10	<0.0001	173	21.23	172	21.10	0.9989
45 to 54	12835	34.86	259	31.78		257	31.53	259	31.78
55 to 64	7341	19.94	208	25.52		210	25.77	208	25.52
65 to 74	3789	10.29	126	15.46		123	15.09	126	15.46
≥75	1297	3.52	50	6.14		52	6.38	50	6.14
Mean ± SD	50.77		54.75		<0.0001	54.51		54.75		0.6823
Gender
Men	31434	85.37	717	87.98	0.0367	722	88.59	717	87.98	0.7002
Women	5389	14.63	98	12.02		93	11.41	98	12.02
Comorbidity
Hypertension	5623	15.27	248	30.43	<0.0001	257	31.53	248	30.43	0.6298
Diabetes mellitus	3399	9.23	178	21.84	<0.0001	183	22.45	178	21.84	0.7655
Dyslipidemia	1828	4.96	72	8.83	<0.0001	64	7.85	72	8.83	0.4737
Chronic kidney disease	279	0.76	23	2.82	<0.0001	23	2.82	23	2.82	1.0000
Heart failure	314	0.85	38	4.66	<0.0001	34	4.17	38	4.66	0.6297
Atrial fibrillation	162	0.44	16	1.96	<0.0001	13	1.60	16	1.96	0.5740
Gastrointestinal ulcer	2968	8.06	70	8.59	0.5836	76	9.33	70	8.59	0.6028
Ischemic heart disease	1233	3.35	139	17.06	<0.0001	137	16.81	139	17.06	0.8949
Peripheral vascular disease	87	0.24	8	0.98	<0.0001	6	0.74	8	0.98	0.5914
Deep venous thrombosis	41	0.11	11	1.35	<0.0001	9	1.10	11	1.35	0.6527
Prescribed drug
ACEI	550	1.49	55	6.75	<0.0001	51	6.26	55	6.75	0.6878
ARB	274	0.74	30	3.68	<0.0001	37	4.54	30	3.68	0.3825
Beta blocker	118	0.32	8	0.98	0.0012	8	0.98	8	0.98	1.0000
CCB	51	0.14	13	1.60	<0.0001	15	1.84	13	1.60	0.7030
NSAIDs	13898	37.74	402	49.33	<0.0001	415	50.92	402	49.33	0.5196
PPI	1335	3.63	82	10.06	<0.0001	83	10.18	82	10.06	0.9346
Statin	84	0.23	13	1.60	<0.0001	10	1.23	13	1.60	0.5287

PSM, propensity score matching; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor.